Celldex Therapeutics (CLDX) Institutional Ownership
13F filers reported holding 23.7% of Celldex Therapeutics (CLDX) shares as of Sep 30, 2026, across 108 filers.
- Held by 13F filers
- 23.7%
- Sep 30, 2026
- 13F filers
- 108
- quarter ended Sep 30, 2026
- 13F value
- $603.4M
- 18.6M shares
- Quarter's fund flow
- Mild accumulation
- 18 new · 11 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | Lawver Teri L | SVP & Chief Commercial Officer | Acquired · Grant / award | 90,000Incentive Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Jimenez Freddy A. | SVP & GENERAL COUNSEL | Acquired · Grant / award | 93,000Incentive Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Torres Denice | director | Acquired · Grant / award | 26,000Non-Qualified Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | Acquired · Grant / award | 95,000Incentive Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Cavanaugh Sarah | SVP OF CORP AFFAIRS & ADMIN. | Acquired · Grant / award | 95,000Incentive Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Martin Samuel Bates | SVP AND CFO | Acquired · Grant / award | 93,000Incentive Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Jain Rita | director | Acquired · Grant / award | 26,000Non-Qualified Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Crowley Elizabeth | SR. VP & CPDO | Acquired · Grant / award | 100,000Incentive Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Young Diane C. | SVP, CHIEF MEDICAL OFFICER | Acquired · Grant / award | 57,000Incentive Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | NEIL GARRY ARTHUR | director | Acquired · Grant / award | 26,000Non-Qualified Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Cohen Cheryl | director | Acquired · Grant / award | 26,000Non-Qualified Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Brownlie Keith L | director | Acquired · Grant / award | 26,000Non-Qualified Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | Marucci Anthony S | PRESIDENT & CEO | Acquired · Grant / award | 375,000Incentive Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | KELER TIBOR | EXECUTIVE VP & CSO | Acquired · Grant / award | 115,000Incentive Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | CONRAD HERBERT J | director | Acquired · Grant / award | 26,000Non-Qualified Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | PEPIN RONALD | SR. VP & CBO | Acquired · Grant / award | 20,000Incentive Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | MARINO JAMES J | director | Acquired · Grant / award | 26,000Non-Qualified Stock Option (right to buy) | — | ↗ |
| Jun 25, 2026 | PENNER HARRY JR | director | Acquired · Grant / award | 26,000Non-Qualified Stock Option (right to buy) | — | ↗ |
| Jan 2, 2026 | Martin Samuel Bates | SVP AND CFO | Acquired · Option exercise | 4,817 | $10.38 | ↗ |
| Jan 2, 2026 | Martin Samuel Bates | SVP AND CFO | Disposed · Option exercise | 4,817Incentive Stock Option (Right to Buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Celldex Therapeutics do institutions hold?
13F filers reported holding 23.7% of Celldex Therapeutics' shares as of Sep 30, 2026, across 108 filers.
How many 13F filers hold Celldex Therapeutics?
Celldex Therapeutics was held by 108 13F filers as of Sep 30, 2026.
Not investment advice.

